Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. When considering the significantly lower number of vials per patient and the slight, non significant, increase in the delivery rate with recombinant follicle-stimulating hormone (r-FSH), the analysis showed a 9.4% reduction in the overall therapy cost per born baby in favour of r-FSH.